6 stories mentioning TYO:4568
Every FINWIRES story that references TYO:4568, newest first.
Daiichi Sankyo (TYO:4568) has an average rating of buy and mean price target of 4,662.67 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Daiichi Sankyo (TYO:4568) has rescheduled the announcement of its consolidated financial results for the fiscal year 2025 from April 27 to May 11, citing the need for additional time to finalize figures.The delay is primarily due to a review of supply plans for its oncology portfolio, which requires further deliberation to reasonably estimate loss provisions related to contracts with manufacturers, according to a Tokyo bourse filing on Monday.The company also moved the announcement of its 5-year Business Plan (FY2026-FY2030) from May 19 to align with the new results date on May 11.
Japanese shares closed nearly 1% higher on Friday after data showed inflation remained contained in March, reinforcing expectations that the Bank of Japan will refrain from raising interest rates next week.The Nikkei 225 rose nearly 1%, or 575.95 points, to close at 59,716.18.Core consumer prices, excluding fresh food, rose 1.8% year on year in March, matching forecasts and accelerating from 1.6% in February. Energy subsidies continued to limit price pressures despite higher fuel costs linked to Middle East tensions.The data showed energy prices fell 5.7%, a smaller drop than the previous month, while nonperishable food inflation eased. A separate core-core gauge, which strips out energy, rose 2.4%.On the corporate front, Shares of Daiichi Sankyo (TYO:4568) fell about 10% after the company delayed its earnings release and five-year plan while reviewing oncology supply plans, even as it raised its full-year profit outlook on foreign exchange gains.Shares of Renesas Electronics (TYO:6723) dropped about 5% despite reporting a 162% jump in first-quarter profit and strong revenue growth, with the company flagging near-term volatility and issuing only a six-month outlook.Shares of SoftBank Group (TYO:9984) rose 2% after a report said its mobile unit plans to convert part of an Osaka plant into a large-scale battery production site to support AI data centers.
Daiichi Sankyo (TYO:4568) raised its attributable profit forecast for the fiscal year ended March 31 to 2.5 billion yen from 1.7 billion yen previously, according to a Tokyo bourse filing on Friday.The pharmaceutical firm now expects earnings per share to be 103.26 yen, up from the earlier forecast of 70.16 yen, while the estimate for net sales has been slightly increased to 35.8 billion yen from 35.3 billion yen.The upward revision is primarily driven by a weaker Japanese yen compared with the company's initial assumption of 151 yen per U.S. dollar, resulting in significant foreign exchange gains on foreign currency-denominated assets and liabilities.For the full year, the company recorded total foreign exchange gains of 609 million yen as non-operating income, though this was partially offset by a 227 million yen allowance for doubtful accounts and 301 million yen in derivative valuation losses.Despite these offsets, the company expects ordinary profit to significantly exceed prior forecasts, while the year-end dividend forecast remains unchanged.
Daiichi Sankyo (TYO:4568) is delaying the release of its consolidated results for the year ended March 31, 2026, to May 11 from April 27 as it requires more time to finalize financial figures, according to a Friday filing on the Tokyo Stock Exchange.Shares of the company plunged nearly 10% in morning trade Friday.The company is reviewing supply plans for its oncology portfolio and development pipeline amid shifting business conditions, which is extending deliberations over estimates for loss provisions tied to contracts with manufacturers.Daiichi Sankyo will also move the release of its five-year business plan for fiscal 2026 through fiscal 2030 to May 11 from May 19 to present both disclosures together for investors.
Suntory Beverage & Food (TYO:2587) is set to acquire Daiichi Sankyo's (TYO:4568) over-the-counter drug unit for about 200 billion yen as the beverage maker expands its health-related business, Nikkei reported WednesdayThe deal would see Daiichi Sankyo divest its healthcare arm, which produces products such as painkiller Loxonin, stomach medicine Gaster 10 and cold remedy Lulu, according to the report.Suntory is seeking to diversify beyond alcoholic beverages as consumption trends shift, while Daiichi Sankyo is expected to focus resources on prescription drugs amid rising research and development costs, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)